

# Charts to the statement at the Annual Shareholders' Meeting in Essen (Germany) on August 31, 2020, 10 a.m.

Christian Kullmann, Chairman of the Executive Board of Evonik Industries AG

# Dealing with the coronavirus crisis at Evonik



## Health

- High standards of hygiene at our sites
- Comprehensive pandemic plan



## Delivery capability

- Company-wide team to ensure availability to deliver
- Timely action to counter bottlenecks



## Social Responsibility

- Supply of disinfectants
- Donation of high-performance polymers for medical-grade protective equipment

# Strategy implementation over the last 20 months

## New divisional structure from 1 July 2020

Chemical operative segments transferred in four **divisions** with **clear strategic roles**

## Desinvestment

Divestment of the cyclical **methacrylates business** in 2019

## Further optimization of cost basis

**SG&A Program** to reduce selling and administrative expenses – **€ 20 m** ahead of plan in 2019

## Acquisitions

**PeroxyChem** and **Porocel** to further strengthen the quality of our portfolio

## Strong operating performance in 2019

**Sales**

**€13,108**  
million

**Adjusted EBITDA**


**€2,153**  
million

**Adjusted earnings per share**


**€1.94**

# Segment operating performance in 2019


## Nutrition & Care




## Resource Efficiency



## Performance Materials




## Stable dividend and high dividend yield of over 4 percent



<sup>1</sup> Proposal including the advance payment

# Outlook 2020 – earnings between €1.7 bn and €2.1 bn expected



# 1st half-year 2020 – largely stable performance of our growth segments


- Operating performance of the first half-year impacted by coronavirus crisis
- **Nutrition & Care** and **Resource Efficiency** largely stable
- **Performance Materials** held back by drop in the oil price
- Sales: € 6,069 m
- Adjusted EBITDA: € 970 m
- Adjusted earnings per share: € 0.73



# Evonik shares – price performance in 2019 and 2020


## Price performance 2019

Evonik: +25%    Peers in the chemicals sector<sup>1</sup>: +29%  
MDAX: +28%



## Price performance 2020

Evonik: -9%    Peers in the chemicals sector<sup>1</sup>: -10%  
MDAX: -5%



<sup>1</sup> Definition of the peers in the chemicals sector: Arkema, BASF, Covestro, Clariant, DSM, Lanxess, Solvay



**EVONIK**

**Leading Beyond Chemistry**